Aerovate Therapeutics Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Tim Noyes
Algemeen directeur
US$3.1m
Totale compensatie
| Percentage CEO-salaris | 19.1% |
| Dienstverband CEO | 3.5yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 3.5yrs |
Recente managementupdates
Recent updates
Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely
Oct 01
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Jun 11Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
May 24Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 09We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate
Oct 17Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Jul 04Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 28A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jan 06Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Oct 14Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
Jul 01We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth
Jan 22Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Sep 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$85m |
| Jun 30 2024 | n/a | n/a | -US$88m |
| Mar 31 2024 | n/a | n/a | -US$82m |
| Dec 31 2023 | US$3m | US$586k | -US$76m |
| Sep 30 2023 | n/a | n/a | -US$70m |
| Jun 30 2023 | n/a | n/a | -US$64m |
| Mar 31 2023 | n/a | n/a | -US$57m |
| Dec 31 2022 | US$704k | US$563k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$5m | US$437k | -US$23m |
Compensatie versus markt: De totale vergoeding ($USD 3.07M ) Tim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.07K ).
Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.
CEO
Tim Noyes (62 yo)
3.5yrs
Tenure
US$3,070,657
Compensatie
Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 3.5yrs | US$3.07m | geen gegevens | |
| CFO & Treasurer | 3.7yrs | US$2.13m | 0.017% $ 13.4k | |
| Founder | 6.3yrs | US$2.88m | 0.049% $ 37.9k | |
| Chief Scientific Officer | 2.3yrs | US$433.20k | 0.0056% $ 4.3k | |
| Chief Medical Officer | 4.5yrs | US$1.63m | 0.019% $ 14.9k | |
| Head of Regulatory Affairs | 4.2yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Development Operations | 2.6yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Quality | 2.3yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Clinical Development | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | 1.8yrs | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AVTE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 3.6yrs | US$3.07m | geen gegevens | |
| Independent Director | 1.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.8yrs | US$568.54k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$225.99k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$174.80k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$218.30k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$185.80k | 0% $ 0 | |
| Independent Chairman of the Board | 1.3yrs | US$363.25k | 0% $ 0 |
3.5yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AVTE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).